Apple Is Quietly Testing a Blood Sugar App. Here's What That Means.

Apple tested a blood-sugar app in 2024, signaling the company's interest in helping people track and manage diabetes. The move matters because the diabetes technology world is changing fast—and Apple may be about to shake things up the way it has in other areas of health.

According to Bloomberg, the study was designed to figure out what kind of blood-sugar tools Apple could build for everyday people, not just patients with serious diabetes. That timing is significant, because the rules around who can use blood-sugar monitoring devices are loosening.

Blood Sugar Monitors Are Going Over-the-Counter

Until recently, devices that continuously track blood sugar were available only by prescription—tools for people with diabetes who needed them for medical care. That is changing. In August 2024, Dexcom released Stelo, a continuous glucose monitor that you can buy without a doctor's prescription, just like you might buy a thermometer or a blood pressure cuff at a pharmacy.

This matters because it opens the door to a much larger group of people. Stelo is designed for people with type 2 diabetes who don't use insulin injections. That group is far bigger than the people currently using prescription glucose monitors.

Other companies are already in the market. Abbott makes FreeStyle Libre devices that have been available for years. But the shift toward over-the-counter versions means more people can access this technology without involving their doctor first.

New Devices Are Getting Smaller and Smarter

Companies are rapidly combining technologies in clever ways. Swiss company Pharmasens built a device called niia that combines a glucose sensor and an insulin pump into one small patch that sticks to your skin and lasts five days. Medtronic's MiniMed 780G does something similar—it automatically adjusts insulin delivery based on blood sugar readings, without you having to calculate doses manually.

The FDA has also approved devices that sit under the skin and send continuous readings to your phone. The bigger picture is that glucose monitoring is becoming less intrusive and more integrated into devices you already wear.

Doctors Are Looking Beyond Simple Blood Sugar Numbers

Blood sugar is important, but it is not the only number that matters for diabetes. Researchers are now paying attention to other markers in your blood that can signal whether diabetes is developing or getting worse. One of these is called 1,5-AHG, which can tell doctors how well your blood sugar has been controlled over weeks. Another is leptin, a substance linked to weight, insulin resistance, and diabetes risk.

Today, doctors typically check fasting blood sugar, a test called A1C (which shows your average blood sugar over months), or glucose tolerance tests. Tomorrow, doctors may have access to a broader picture built from multiple measurements tracked continuously.

Big Tech Is Entering a Medical Device World

The broader context here is that large technology companies like Apple have shown they can bring consumer health tools to millions of people. Apple Watch already tracks heart rate and blood oxygen. The company's Health app pulls together data from many sources. Those capabilities position Apple to potentially enter glucose monitoring—but there are real hurdles.

Glucose monitoring is more tightly regulated than fitness tracking. The FDA approves these devices as medical equipment, and the accuracy standards are high because people with diabetes rely on these numbers to make decisions about medication. Apple would need to meet those standards and convince people that a consumer device can be trusted the same way a prescription device is.

In my view, the most realistic path forward is not Apple replacing dedicated glucose devices, but complementing them. Apple could build tools that help you understand and act on glucose data you already have, much the way it helps you understand your daily activity or sleep.

The practical implications for patients and doctors are worth thinking through. If millions of people start using over-the-counter glucose monitors and sharing data through their phones, doctors will see far richer information about their patients' daily lives. That could improve care—but it also means healthcare providers will need new ways to interpret so much data coming in constantly, rather than just at annual checkups.

There is also a competitive shift happening. Traditional diabetes device makers like Dexcom and Abbott have dominated this space for years. Now they face new competitors with different kinds of money and expertise. Tech companies like Apple play by different rules: they have consumer distribution, software expertise, and the ability to lose money on hardware to build loyalty. That kind of competition can drive innovation quickly.

The question ahead is not whether big tech will move into glucose monitoring—that is already underway. The question is how fast they can navigate the FDA's approval process, and whether they can build tools that actually help people manage their health better, rather than just adding another app to your phone.